TetraLogic Pharmaceuticals Corporation (TLOG)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2015 | 2014 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -34.88 Million | -32.36 Million |
| Net Income | - | - | - | - | -49.72 Million | -35.95 Million |
| Depreciation & Amortization | - | - | - | - | 187.99 Thousand | 125.95 Thousand |
| Deferred income taxes | - | - | - | - | 14.58 Million | -1.07 Million |
| Stock-based compensation | - | - | - | - | 5.68 Million | 3.38 Million |
| Change in working capital | - | - | - | - | 1.08 Million | -2.81 Million |
| Other non-cash items | - | - | - | - | -6.69 Million | 3.96 Million |
| Investing Cash Flow | - | - | - | - | 35.44 Million | -53.97 Million |
| Investments in PPE | - | - | - | - | -77.33 Thousand | -514.85 Thousand |
| Acquisitions | - | - | - | - | - | -12.84 Million |
| Investment purchases | - | - | - | - | -24.41 Million | -66.29 Million |
| Sales/Maturities of investments | - | - | - | - | 59.93 Million | 25.66 Million |
| Other Investing Activities | - | - | - | - | 35.52 Thousand | 20 Thousand |
| Financing Cash Flow | - | - | - | - | 1.79 Million | 44.34 Million |
| Debt repayment | - | - | - | - | -825 Thousand | -44.14 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | 2.61 Million | - |
| Other Financing Activities | - | - | - | - | 2.61 Million | 201.13 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | 1.08 Million | -3383.82 |
| Cash at beginning of period | - | - | - | - | 13.07 Million | 55.13 Million |
| Cash at end of period | - | - | - | - | 15.3 Million | 13.07 Million |
| Capital Expenditure | - | - | - | - | -77.33 Thousand | -514.85 Thousand |
| Effect of forex changes on cash | - | - | - | - | -118.98 Thousand | -69.03 Thousand |
| Net cash flow / Change in cash | - | - | - | - | 2.22 Million | -42.06 Million |
| Free Cash Flow | - | - | - | - | -34.96 Million | -32.88 Million |
| Breakdown | 2022 FY | 2021 FY | 2020 FY | 2019 FY | 2016 Q3 | 2016 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | -8.63 Million | -6.74 Million |
| Depreciation & Amortization | - | - | - | - | 9294.00 | 21.37 Thousand |
| Deferred income taxes | - | - | - | - | 2.85 Million | 92.95 Thousand |
| Stock-based compensation | - | - | - | - | -28.71 Thousand | 563.11 Thousand |
| Change in working capital | - | - | - | - | 983.14 Thousand | -1.67 Million |
| Other non-cash items | - | - | - | - | 2.02 Million | 1.87 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | 300.49 | 656.08 |
| Cash at beginning of period | - | - | - | - | 8.67 Million | 14.54 Million |
| Cash at end of period | - | - | - | - | 5.88 Million | 8.67 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | 4101.00 | -3527.00 |
| Net cash flow / Change in cash | - | - | - | - | -2.79 Million | -5.86 Million |
| Free Cash Flow | - | - | - | - | -2.79 Million | -5.86 Million |
INVENTURE
2401
MTBLY
4995
3359
0HFN